Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770468934501 Cache Key: cqdTagPageBySlug:drug-repurposing fetchCache[cqdTagPageBySlug:drug-repurposing].expirationTime: falsey fetchCache[cqdTagPageBySlug:drug-repurposing]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 2305 -- Key: cqdTagPageBySlug:malnutrition, seconds remaining: 2305 -- Key: cqdPostsByTag:cqd-migrated-tag-24189,1,10, seconds remaining: 2351 -- Key: cqdTagPageBySlug:sirna, seconds remaining: 5611 -- Key: cqdPostsByTag:cqd-migrated-tag-24540,1,10, seconds remaining: 5652 -- Key: cqdTagPageBySlug:rheumatology-case-study, seconds remaining: 5951 -- Key: cqdPostsByTag:cqd-migrated-tag-26709,1,10, seconds remaining: 6007 -- Key: cqdTagPageBySlug:eating-disorders, seconds remaining: 6230 -- Key: cqdPostsByTag:cqd-migrated-tag-4195,1,10, seconds remaining: 6272 -- Key: cqdTagPageBySlug:corneal-epithelial-mapping, seconds remaining: 6600 -- Key: cqdPostsByTag:cqd-migrated-tag-24707,1,10, seconds remaining: 6650 -- Key: cqdTagPageBySlug:hydrogen-sulfide, seconds remaining: 7690 -- Key: cqdPostsByTag:cqd-migrated-tag-24007,1,10, seconds remaining: 7745 -- Key: cqdTagPageBySlug:frank-esper, seconds remaining: 8152 -- Key: cqdPostsByTag:cqd-migrated-tag-21112,1,10, seconds remaining: 8200 -- Key: cqdTagPageBySlug:stampede, seconds remaining: 8850 -- Key: cqdPostsByTag:cqd-migrated-tag-3629,1,10, seconds remaining: 8915 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:drug-repurposing - retrieving from Sanity CCCache.dataFetchCount: 3051 Cache cleanup seconds remaining: 28915
Advertisement
Advertisement
Systems genetics approach sets stage for lab testing of simvastatin and other candidate drugs
Open-source artificial intelligence technology uses human genetic data to find candidate drugs
$14M NIH grant supports research toward medications to prevent progression
BACE1 inhibitor reduces cancer progression in models of glioblastoma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
69% relative risk reduction in large database analysis prompts plans for mechanistic and phase 2 studies
Minimizing the translational gap between preclinical testing and clinical outcomes
deepDTnet receives provisional patent to accelerate drug repurposing and minimize the translational gap in development
Rendered: Sat Feb 07 2026 12:55:34 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
